Skip to main content
Premium Trial:

Request an Annual Quote

Cambridge Antibody Technology Swallows Oxford Glycosciences in Merger

NEW YORK, Jan. 23-Oxford Glycosciences and Cambridge Antibody Technology will merge, the two companies said today.

 

In the merger, CAT will subsume OGS. The new company, to be called Cambridge Antibody Technology, plans a cost-cutting "portfolio review" that will "focus R&D expenditure on the highest quality projects," according to a joint statement. It expects to save approximately £10 million in expenses in its first financial year through eliminating "duplicated activities" in corporate overhead, R&D and real estate.

 

Under the deal, OGS stockholders will receive 0.362 shares of CAT for each share of OGS owned. CAT shareholders will own 64.3 per cent of the new company, and OGS shareholders will own the remainder.

 

Based on yesterday's CAT closing price of 540 pence, each OGS share will be worth 195.5 pence, a premium of 28.2 percent over yesterday's closing price.

 

The merger will leave CAT's senior management in charge, including Chief Executive Officer Peter Chambre, Chief Financial Officer John Aston and chair Peter Garland.

 

OGS chief executive officer David Ebsworth will be asked to join CAT's board as an executive director "to assist in the integration process," according to a statement from the two companies. He plans to remain on the company board as a non-executive director following a portfolio review scheduled to wrap up in November 2003.

 

OGS Chief Scientific Officer Raj Parekh will be asked to join the CAT board as an executive director during the transition and "portfolio review." He plans to remain on the board as a non-executive director subsequent to that. OGS Chief Medical Officer Chris Moyses and Chief Financial Officer Denis Mulhall will be asked to join CAT's executive committee.

 

James Hill, currently an OGS non-executive board member, will be asked to join CAT's board as a non-executive director.

 

The new Cambridge Antibody Technology will have pro forma net cash of £260.1 million as of Dec. 31.

 

The merger is expected to happen in March 2003.

 

For further information, see the company statement.

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.